AB Science (EUR)
AB
Overview
Key Information
Legal Documents
Financials

Overview

SectorHealthcare
Industry-
Day Range8.94 | 9.12
52-Wk Range- | -
Last Close9.00
Mkt Cap (m)401.20
Dividend yield-
ISINFR0010557264
Volume47,374.00
Exchange VenuePAR

Company Profile

AB Science is a pharmaceutical company. It is engaged in research, development, & commercialization of tyrosine kinase inhibitors, therapeutic drugs used in treating cancerous tumors, inflammatory & neuro-degenerative diseases in both humans & animals.

Key Information
Price/Earning-
Price/Book0.00
Price/Sales225.71
P/CF-
Rev Growth (3 year avg)1.37
EPS Growth (3 year avg)-
Operating Margin % -1,112.29
Net Margin %-1,384.28
Return on Equity-
Debt/Equity-

Documents

Annual Report
en 31/12/2019

Please refer to the below issuer website for further documents.

http://www.ab-science.com

Financials

Income Statement
EUR201420152016201720182019
Revenue (m)2.102.281.511.741.701.57
Operating Income (m)-15.20-25.96-30.21-28.40-28.94-17.47
Net Income (m)-16.11-26.72-27.70-27.12-26.06-21.75
Basic EPS-0.49-0.78-0.78-0.75-0.69-0.55
Avg. Diluted Shares Outstanding (m)32.9434.2035.6535.9937.7839.40
Balance Sheet
EUR201420152016201720182019
Current Assets (m)29.5430.6036.1248.6420.7114.09
Non Current Assets (m)1.731.971.891.961.783.66
Total Assets (m)31.2832.5838.0150.6022.4917.74
Current Liabilities (m)14.0017.6120.3418.7119.2019.53
Total Liabilities (m)------
Total Equity (m)-15.68-17.26-4.7110.74-14.96-26.83
Cash Flows
EUR201420152016201720182019
Operating Cash Flows (m)-14.16-23.16-33.52-22.90-26.79-15.16
Capital Expenditure (m)-0.66-0.62-0.52-0.50-0.48-0.39
Figures are quoted in EUR unless stated otherwise
-
No change
9.00
Last Price